Fagron acquired Magilab

FIP advised Fagron on the acquisition of Magilab, acting on the buy side of the transaction. Our support included active involvement throughout the process, with a particular focus on due diligence, equity bridge analysis, and transaction negotiations, contributing to the successful completion of the acquisition.

Business needs:

A global personalized medicine player needed rapid, reliable financial insight when the ongoing DD process stalled, requiring a full-scope, two-week due diligence turnaround to validate EBITDA, assess working capital, and support final negotiations.

FIP approach:

Deal Management

• Took over within 48 hours to rebuild all core analyses from audited data & management inputs

• Delivered an immediate “red-flagpack” and data request listto stabilise the deal process

Due Diligence

• Identified non-core items for EBITDA adjustments & IFRS reclassifications for QoE analysis, confirming pricing

• Assessed customer concentration, inventory ageing & obsolescence

Negotiation support

• Seller attempted to re-open price at SPA signing based on revised EBITDA forecast

• Delivered on-the-spot counter-analysis

• Helped client maintain the originally agreed valuation range

Results:

• Delivered full-scope financial due diligence in <14 days with clear red flags and bridge-ready outputs

• Completed EBITDA normalisation including non-recurring items, accounting adjustments and margin diagnostics

• Prevented a late-stage valuationre-trade by preparing counter-analysis, helping to preserve deal within the initial pricing corridor